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S U M M A R Y
Objectives: The clinical impact of seasonal inﬂuenza is understudied in tropical countries. The aim of this
study was to describe the clinical features and seasonal pattern of inﬂuenza in children hospitalized in
Malaysia, and to identify predictors of severe disease.
Methods: Children hospitalizedwith community-acquired, laboratory-conﬁrmed inﬂuenza at a teaching
hospital in Kuala Lumpur,Malaysia during 2002–2007were identiﬁed retrospectively. Clinical datawere
collected, and predictors of severe disease were identiﬁed by multivariate logistic regression. All
inﬂuenza cases from 1982 to 2007 were also analyzed for seasonal patterns.
Results: A total of 132 children were included in the study, 48 (36.4%) of whom had underlying medical
conditions. Themean agewas 2.5 years and 116 (87.9%)were<5 years old. Themost common presenting
features were fever or history of fever, cough, rhinitis, vomiting, and pharyngitis. Severe inﬂuenza was
seen in 16 patients (12.1%; nine previously healthy), including 12 (9.1%; eight previously healthy)
requiring intensive care. There were three (2.3%) deaths. Severe disease was associated with age <12
months, female sex, and absence of rhinitis on admission. Inﬂuenza was seen year-round, with peaks in
November–January and May–July.
Conclusions: Seasonal inﬂuenza has a considerable impact on children hospitalized in Malaysia, in both
the healthy and those with underlying medical conditions.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Inﬂuenza is a major cause of respiratory infections worldwide,
resulting in considerable morbidity and mortality. Children aged
<5 years and those with underlying medical conditions are at
particular risk.1 Much of the data on pediatric inﬂuenza comes
from developed countries in temperate climates, which have
distinct seasonal peaks in winter.2 Reported hospitalization rates
have ranged from 0.9 to 3.2 per 1000 children aged <2 years.3–6
Vaccination of children against seasonal inﬂuenza is therefore
widely recommended in temperate countries.7,8
In contrast, much less is known about the clinical impact of
childhood seasonal inﬂuenza in tropical countries, mainly due to a
perception that inﬂuenza is not a signiﬁcant health problem9 and
to a lack of diagnostic virology facilities. However, studies from
tropical Singapore10 and subtropical Hong Kong11 have indicated* Corresponding author. Tel.: +60 3 7949 2184; fax: +60 3 7967 5753.
E-mail address: jicsam@um.edu.my (I.-C. Sam).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.10.005that the burden of inﬂuenza equals or even exceeds rates seen in
temperate countries. With avian inﬂuenza (H5N1) and pandemic
inﬂuenza A (H1N1) originating from developing countries, a
detailed understanding of inﬂuenza becomes increasingly critical
in these less well-studied areas.
This study aimed to describe the clinical features of children
hospitalized with laboratory-conﬁrmed seasonal inﬂuenza in
tropical Malaysia. In particular, we focused on clinical presenta-
tions, complications, and predictors of severe disease. Inﬂuenza
cases over a 25-year period were also examined for seasonal
patterns.
2. Materials and methods
2.1. Study population
The University Malaya Medical Centre (UMMC) is a 900-bed
teaching hospital in Kuala Lumpur, Malaysia. It has 130 pediatric
beds and approximately 6000 pediatric admissions annually. All
pediatric patients <15 years of age who were admitted with
laboratory-conﬁrmed inﬂuenza from 2002 to 2007, were identiﬁedses. Published by Elsevier Ltd. All rights reserved.
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conﬁrmed inﬂuenzawas deﬁned as the detection of inﬂuenza virus
antigen by immunoﬂuorescence or isolation of inﬂuenza virus,
froma clinical specimen. Nosocomial infections, deﬁned as onset of
inﬂuenza more than 48 h after admission, were excluded.
2.2. Study design
This study was approved by the hospital’s medical ethics
committee. The medical records of all identiﬁed cases were
retrospectively reviewed, and data on demographics, clinical
presentation, laboratory tests, treatment, and outcomes were
collected using a standard form.
A patient was deﬁned as having severe inﬂuenza disease in the
event of death, admission to the pediatric intensive care unit
(PICU), ventilation, or a serious inﬂuenza-associated complication
present on admission, such as myocarditis, meningitis, or sepsis/
hypotension requiring inotropic support. Severe bacterial super-
infections due to organisms other than those usually associated
with inﬂuenza (e.g., Staphylococcus aureus and Streptococcus
pneumoniae) were considered to be co-existing with, rather than
directly caused by, inﬂuenza. We identiﬁed underlying high-risk
medical conditions that predispose to severe disease, as described
by the Advisory Committee on Immunization Practices (ACIP).7
2.3. Virology
Nasopharyngeal aspirates were routinely screened for respira-
tory viruses including inﬂuenza A and Bwith the Respiratory Virus
Panel direct immunoﬂuorescence assay (Millipore, Billerica, USA).
All respiratory specimens were inoculated into Madin Darby
canine kidney (MDCK), Vero, and A549 cells, and monitored daily
for cytopathic effect (CPE) for 14 days. Hemadsorptionwith human
type O blood was performed on MDCK cells with no CPE to detect
the presence of inﬂuenza virus. Direct immunoﬂuorescence was
used to conﬁrm the identity of respiratory virus isolates.
2.4. Statistical analysis
Statistical analysis was carried out using SPSS 15.0 (SPSS Inc.,
Chicago, USA). Descriptive analysis was performed on the data.
For univariate analysis, Mann–Whitney U-tests were used for
continuous variables and Chi-square or Fisher’s exact tests were
used for categorical variables. A two-tailed p-value of <0.05 was
considered signiﬁcant. To determine predictors for severe disease,
univariate logistic regression was carried out on selected
variables. Odds ratios (OR) with 95% conﬁdence intervals (CI)
were calculated. Variables with a p-value of <0.25 were then
considered in the multivariate regression model, using the
likelihood ratio test. The resulting parsimonious model was
tested for collinearity and interactions. To assess the ﬁnal model,
the Hosmer and Lemeshow goodness-of-ﬁt test was performed,
and the area under the curve of the receiver operating
characteristic curve was calculated.
2.5. Seasonality
The dates of all specimens with laboratory-conﬁrmed inﬂuenza
from 1982 to 2007 were obtained from laboratory records. These
included specimens from nosocomial cases and samples from
external laboratories. Cases were aggregated for each calendar
month, to minimize ascertainment bias due to improvements in
awareness or laboratory techniques. The percentage of conﬁrmed
inﬂuenza cases over the number of specimens tested was also
calculated, to minimize the effect of the varying numbers of
samples received in the laboratory over the years.3. Results
3.1. Patients
A total of 160 pediatric inpatients with laboratory-conﬁrmed
inﬂuenza were seen in 2002–2007, ranging from 19 to 32 patients
yearly, or 0.2% to 0.6% of annual pediatric admissions (mean 0.3%).
Of these, 25 (15.6%) had nosocomially acquired inﬂuenza, and the
medical records for a further three (1.9%) were unavailable. The
remaining 132 (82.5%) patients were included in the study. The
mean age was 2.5  2.9 years; 116 (87.9%) patients were <5 years
old and 75 (56.8%) were <2 years old.
There were 48 (36.4%) children with ACIP-designated high-risk
medical conditions, including asthma (n = 19), immunosuppres-
sion (n = 11), and chronic cardiovascular (n = 10), neurological or
neuromuscular (n = 7), hepatic (n = 4) and other pulmonary (n = 3)
disorders. Four children had more than one high-risk condition.
Further demographic data are shown in Table 1.
3.2. Clinical data
The common presenting clinical features are shown in Table 2.
Although fever was present in only 65 (49.2%) children on
admission, 61 of the remaining 67 reported a prior history of
fever. The mean duration of symptoms was 5.0  4.3 days (median
4 days; range 1–21 days). The mean length of hospital stay was
6.2  5.5 days (median 4 days; range 1–26 days), excluding one
patient with a prolonged stay for social reasons. Antibiotics were
given to 108 (81.8%) patients, most commonly amoxicillin–clavula-
nate (63 children). No antivirals were used.
Severe inﬂuenza was seen in 16 (12.1%) patients, nine of whom
were previously healthy. These included 12 (9.1%) children
admitted to the pediatric intensive care unit (PICU), eight of
whom were previously healthy. All were transferred to the PICU
directly or on the day following admission, except for one child
who was transferred 19 days after admission with nosocomial
pneumonia. The children admitted to the PICU had pneumonia
(n = 8), sepsis (n = 2), S. pneumoniae meningitis (n = 1), and
exacerbation of underlying heart failure (n = 1). A total of 12
children were ventilated.
Five children had co-existing bacteremia (non-typhoidal
Salmonella species (n = 2), Enterobacter species (n = 1), and line-
associated infections with Streptococcus (n = 1) and coagulase-
negative Staphylococcus species (n = 1)). Three patients had co-
existing bacterial gastroenteritis due to Salmonella species (n = 2)
and Campylobacter jejuni (n = 1). There were ﬁve patients co-
infected with other respiratory viruses, including respiratory
syncytial virus (RSV), adenovirus, and parainﬂuenza virus. There
were no differences in demographic and clinical features between
patients infected with inﬂuenza A (n = 97, 73.5%) or B (n = 35,
26.5%).
There were three (2.3%) deaths. One was a 6-month old with no
notable medical history, who had sepsis, multiorgan failure, and
concurrent Campylobacter gastroenteritis.12 The other two chil-
dren, a 1-year-old with duodenal atresia and parenteral nutrition-
associated cholestasis and a 4-year-old with relapsed acute
leukemia, both died of pneumonia.
Compared to previously healthy patients, univariate analysis
showed that the 48 patients with ACIP conditions were older
(mean 3.3 vs. 2.1 years, z = 2.2, p = 0.026), had a shorter duration
of symptoms (mean 3.5 vs. 5.9 days, z = 2.7, p = 0.006), weremore
likely to be given antibiotics (91.7% vs. 76.2%, Chi-square = 4.9,
p = 0.034), and stayed in hospital for longer (mean 9.3 vs. 4.4 days,
z = 5.8, p<0.001). Patients with ACIP conditions weremore likely
to have severe inﬂuenza (14.6% vs. 10.7%), but this difference was
not signiﬁcant.
Table 1
Predictors of severe inﬂuenza disease in hospitalized children (N=132)
Predictor n (%) No. with severe
inﬂuenza, n (%)
Crude OR (95% CI) p-Value Adjusted OR (95% CI) p-Value
Age
<12 months 43 (32.6) 11 (25.6) 5.78 (1.86–17.93) 0.02 8.76 (2.31–33.14) 0.01
>12 months 89 (67.4) 5 (5.6) 1.0
Sex
Male 75 (56.8) 6 (8) 1.0
Female 57 (43.2) 10 (17.5) 2.45 (0.83–7.19) 0.10 3.69 (1.01–13.43) 0.048
Ethnicity
Malay 97 (73.5) 11 (11.3) 1.0
Indian 18 (13.6) 0 0 1.00
Chinese 15 (11.4) 4 (26.7) 2.84 (0.77–10.49) 0.12 NSc
Othera 2 (1.5) 1 (50) – –
ACIP condition
No 84 (63.6) 9 (10.7) 1.0
Yes 48 (36.4) 7 (14.6) 1.42 (0.49–4.10) 0.51
Duration of symptoms (days), mean 5.0 – 0.84 (0.68–1.03) 0.13 NSc
Clinical features on admissionb
Rhinitis
No 33 (25) 10 (30.3) 6.74 (2.22–20.46) 0.001 8.66 (2.43–30.80) 0.001
Yes 99 (75) 6 (6.1) 1.0
Cough
No 12 (9.1) 4 (33.3) 4.50 (1.18–17.29) 0.03 NSc
Yes 120 (90.9) 12 (10) 1.0
Seizures
No 117 (88.6) 12 (10.3) 1.0
Yes 15 (11.4) 4 (26.7) 3.18 (0.88–11.57) 0.08 NSc
Inﬂuenza diagnosis
Positive IF 72 (54.5) 9 (12.5) 1.0
Virus culture only 60 (45.5) 7 (11.7) 0.96 (0.33–2.75) 0.94
Inﬂuenza type
A 97 (73.5) 13 (13.4) 1.0
B 35 (26.5) 3 (8.6) 0.61 (0.16–2.27) 0.46
Respiratory virus co-infection
No 127 (96.2) 15 (11.8) 1.0
Yes 5 (3.8) 1 (20) 4.00 (0.67–23.86) 0.13 NSc
OR, odds ratio; CI, conﬁdence interval; ACIP, Advisory Committee on Immunization Practices;7 IF, immunoﬂuorescence; NS, not signiﬁcant.
a Not analyzed as heterogeneous (non-speciﬁc) group.
b Other clinical features not found to be associated with severe disease, and not shown in this table: fever, vomiting, sore throat, diarrhea, rash, and stridor.
c Tested in the multivariate analysis and found not to be signiﬁcantly associated with severe disease.
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The ﬁnal multivariate regression model (Table 1) showed that
severe disease was associated with age <12 months (OR 8.76, 95%
CI 2.31–33.14), female sex (OR 3.69, 95% CI 1.01–13.43), and
absence of rhinitis at presentation (OR 8.66, 95% CI 2.43–30.80).
This model had satisfactory ﬁt and discrimination (goodness-of-ﬁt,
p = 0.72; area under the curve = 0.83). Notably, the presence of an
ACIP condition was not associated with severe disease, even when
forced into the multivariate model.Table 2
Clinical symptoms on admission of 132 children with commu-
nity-acquired, laboratory-conﬁrmed seasonal inﬂuenza
Clinical symptom n (%)
Fever/history of fever 126 (95.5)
Cough 120 (90.9)
Coryza/rhinitis 99 (75)
Vomiting 45 (34.1)
Sore throat 27 (20.5)
Diarrhea 21 (15.9)
Seizures 15 (11.4)
Rash 12 (9.1)
Stridor 5 (3.8)3.4. Seasonality
Between 1982 and 2007, there were 364 laboratory-conﬁrmed
inﬂuenza cases detected from 12 216 clinical specimens (Fig. 1). As
a proportion of clinical specimens tested, the monthly rate ofFig. 1. Seasonal pattern of laboratory-conﬁrmed inﬂuenza cases diagnosed in 1982–
2007, presented as absolute numbers (bars), and as a percentage of total samples
tested (line).
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There was year-round inﬂuenza activity, with peaks in November–
January and May–July.
4. Discussion
We found that inﬂuenza had considerable clinical impact on
admitted children with and without pre-existing medical condi-
tions. As seen in previous studies,3–6,8,13,14 most of the total
admissions (84/132 children (63.6%)), children with severe
disease (9/16 children (56.3%)), and PICU admissions (8/12
children (66.7%)) were previously healthy, and a majority
(87.9%) were <5 years old. The PICU admission rate (9.1%) and
disease severity were comparable to those found in other
countries.3–6,8,13,14 The mean length of inpatient stay was 6.2
days, suggesting considerable socioeconomic losses in terms of
school and work days lost. There were three deaths (2.3%) in this
study, although inﬂuenza-related deaths are rare in children, at
0.2–0.3 per 100 000 person-years in those aged <4 years.15 Our
rate is basedon abiased sample of hospitalizedpatients. However,
the number of children with inﬂuenza is likely to be under-
estimated in this study due to the relative insensitivity of
diagnosis by immunoﬂuorescence and virus isolation when
compared to PCR. Furthermore, almost half of reported inﬂuen-
za-associated deaths may occur in the emergency department or
at home, and not in an inpatient setting.16 Therefore, there is a
critical need for further study of the true inﬂuenza burden in
Malaysia.
In this study, severe inﬂuenza was associated with age <12
months (25.6% of this age group had severe disease), female sex,
and the absence of rhinitis at presentation. The latter association
has been reported previously,4 and these symptoms may
indicate an upper respiratory tract infection rather than
potentially serious involvement of other organs. Underlying
medical conditions are known to predispose to severe dis-
ease,7,13 but we did not ﬁnd this in our patients, in agreement
with another study.4 This may be due to the small sample size,
or because healthy children with mild inﬂuenza may be less
likely to be brought to hospital than children with medical
conditions. In support of this, hospitalized children with ACIP
conditions had signiﬁcantly shorter duration of symptoms,
suggesting they had sought medical attention earlier.
The incidence and overall burden of inﬂuenza inMalaysia is not
known, as surveillance data are limited. In a previous hospital-
based study, inﬂuenza caused 6.2% of respiratory virus infections,
ranking third behind RSV and parainﬂuenza.17 We were unable to
calculate the incidence rate of inﬂuenza hospitalization, as the
catchment population served by our hospital is not clearly deﬁned.
However, laboratory-conﬁrmed inﬂuenza accounted for 0.3% of all
pediatric admissions to our hospital. This is comparable to a recent
study estimating that RSV infection, widely recognized as a cause
of substantial morbidity, causes one in 334 (0.3%) hospitalizations
of children <5 years in the USA.18
Despite the growing evidence that inﬂuenza is a signiﬁcant
health problem in developing countries, the usage of inﬂuenza
vaccine is extremely low.19 In Malaysia, there are no recommen-
dations for inﬂuenza vaccination in children, and the unknown
burden of inﬂuenza precludes cost–beneﬁt analysis. If Malaysia
followed the 2006 ACIP recommendations for vaccinating all
children aged 6–59 months and those with high-risk conditions,
and taking the lower limit of reported vaccine efﬁcacy of 54–91%,7
up to 57 of the 131 hospitalizations in this study may have been
prevented. In practice, however, inﬂuenza vaccine uptake is low,
even in developed countries with adequate resources. In the USA,
of 90 cases of inﬂuenza-associated death in 2004–2007 with
indications for vaccination, only 21% had been vaccinated.16An indirect beneﬁt of greater use of the seasonal inﬂuenza
vaccine would be to increase worldwide vaccine production
capacity, which is currently insufﬁcient for all countries. This has
become critically apparent during the current pandemic, whereby
most of the new vaccines will be supplied to developed countries,
the main users of seasonal vaccine.20
The few available studies of seasonality suggest that in the
tropics, inﬂuenza occurs throughout the year, and peaks of activity
may occur more than once and last longer than in temperate
countries.21 Our ﬁndings support this and the limited Malaysian
data currently available, a national survey of 466 inﬂuenza cases
from 1997 to 2005.22 Within Southeast Asia, the Malaysian
inﬂuenza seasonal pattern of year-round activity with biannual
peaks (May–July, November–January) is most similar to neighbor-
ing Singapore10 and Vietnam,23 rather than the year-round activity
with single peaks seen in Indonesia (October–January)24 and
Thailand (June–September).25 As there are seasonal differences
within the region, inﬂuenza vaccination programs need to be
tailored to individual countries.
In conclusion, community-acquired seasonal inﬂuenza has an
important impact on children hospitalized in tropicalMalaysia. Over
a 25-year period, inﬂuenza was seen year-round, with biannual
peaks.However,detailedknowledgeoftheepidemiologyof inﬂuenza
is lacking inMalaysia, and theburdenofdisease is underappreciated.
Inﬂuenza vaccine is not widely used, but may beneﬁt Malaysian
children. To further understand inﬂuenza disease in Malaysia,
particularly if routine vaccination is considered, comprehensive,
prospectively-collected surveillance data are required.
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